June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Ophthalmic Immune-related Adverse Events following anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology IRIS® Registry
Author Affiliations & Notes
  • Michel Sun
    Department of Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Scott P. Kelly
    American Academy of Ophthalmology, San Francisco, California, United States
  • Apoorva L. Mylavarapu
    Department of Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Anne L Coleman
    Department of Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
    Department of Epidemiology, Fielding School of Public Health, UCLA, Los Angeles, California, United States
  • Gary N Holland
    Department of Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Fei Yu
    Department of Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Sukhminder Singh
    American Academy of Ophthalmology, San Francisco, California, United States
  • Stephen Hsu
    American Academy of Ophthalmology, San Francisco, California, United States
  • Flora Lum
    American Academy of Ophthalmology, San Francisco, California, United States
  • Lynn K Gordon
    Department of Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Michel Sun, None; Scott Kelly, None; Apoorva Mylavarapu, None; Anne Coleman, None; Gary Holland, None; Fei Yu, None; Sukhminder Singh, None; Stephen Hsu, None; Flora Lum, None; Lynn Gordon, None
  • Footnotes
    Support  Research to Prevent Blindness, Inc
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2055. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michel Sun, Scott P. Kelly, Apoorva L. Mylavarapu, Anne L Coleman, Gary N Holland, Fei Yu, Sukhminder Singh, Stephen Hsu, Flora Lum, Lynn K Gordon; Ophthalmic Immune-related Adverse Events following anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology IRIS® Registry. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2055.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The study of ophthalmic immune-related adverse events (OirAEs) is of integral importance in the evolving field of cancer immunotherapy. This study seeks to quantify incidence and recurrence rates of OirAEs by immune checkpoint inhibitor (ICI) status in a longitudinal big-data registry.

Methods : This retrospective registry study examined patients newly diagnosed with OirAEs between Jan 1, 2013 and Dec 31, 2017 in the American Academy of Ophthalmology IRIS® Registry. The primary exposure of interest was prior initiation of ICIs. Incidence of OirAEs within 1 year following initiation of ICIs, including anti–PD-1 (programmed cell death 1) or anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) therapy was determined. Incidence rate ratios (IRR) were derived by comparing incidence of OirAEs after ICIs vs rates of non-immune related ocular complications in the entire registry population. Rates of OirAEs in patients with a past history of ocular inflammation or other specific ophthalmic condition prior to initiation of ICIs were further examined.

Results : A total of 3,121 patients were identified to have received anti-CTLA-4 or anti-PD-1, 70 of whom developed an OirAE. Higher rates of OirAEs were seen in the black population (8.1%) compared to whites (2.0%). Incidence rates for uveitis-specific OirAEs were found to be 5,532 per 100,000 for ipilimumab (anti-CTLA-4), 2,037 per 100,000 for nivolumab (anti–PD-1), 1,827 per 100,000 for pembrolizumab (anti–PD-1), 4,444 per 100,000 for combination ipilimumab/nivolumab, and 2,294 per 100,000 among all ICIs. In comparison to ocular complication incidence rates among all patients, rates of OirAEs among patients on ICI therapy were found to be much greater (anterior uveitis IRR=17.6, intermediate/posterior/panuveitis IRR=18.2). Among patients with a prior history of uveitis or other ocular condition anytime prior to ICI initiation, recurrence rates of ocular complications via subsequent OirAEs were high (51.1% for intermediate/posterior/panuveitis, 38.9% for anterior uveitis).

Conclusions : For patients initiating ICI therapy, early coordination with ophthalmological subspecialist care is important, as rates of OirAEs are elevated compared to ocular complication rates in the entire registry population and patients with a previous history of any uveitis or autoimmune ocular disease are at high risk of recurrence.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×